14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABOS vs USIN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ABOS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–3 Matrix Metrics)
ABOS Overall Winner
6-Pillar Tally: ABOS 4 – 0 USIN (2 Tie)
Matrix Metrics: ABOS 5 – 3 USIN
As of Nov 20, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over USIN (USIN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABOS carries a Unified Composite Score of 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin), whereas USIN carries 53.1/100 (HOLD) at $48.19 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While USIN currently prints a higher short-term Unified Composite Score (53.1/100 HOLD vs. ABOS 49.2/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.8); meanwhile USIN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs USIN. Trailing 12-month operating profitability (ABOS 0.0% vs USIN N/A) and valuation multiples (ABOS N/M vs USIN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABOS vs USIN Key Questions & Quantitative Answers
As of Nov 20, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over USIN (USIN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABOS carries a Unified Composite Score of 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin), whereas USIN carries 53.1/100 (HOLD) at $48.19 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While USIN currently prints a higher short-term Unified Composite Score (53.1/100 HOLD vs. ABOS 49.2/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.8); meanwhile USIN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABOS leads the Growth & Scale pillar: ABOS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with USIN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABOS generates $329,000 in USD-normalized revenue versus N/A for USIN. In operating R&D and SG&A reinvestment, ABOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for USIN.
ABOS and USIN trade at balanced relative valuation multiples. ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas USIN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABOS (-162.7% ROE) versus USIN (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.62β · 326% Vol realized risk). By comparison, USIN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 7% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.